本文对我院收治的肿瘤化疗患者采用血小板生成素(rhTPO)进行预防,取得了良好的临床效果,现报告如下。1资料与方法1.1临床资料回顾性分析2007年2月至2012年2月我院收治的52例恶性肿瘤患者的临床资料,所有患者为恶性肿瘤化疗后经病理组织学或细胞学检查确诊血细胞减少,血小板计数均低于75×109/L,预计生存期均大于3个月,血清转氨酶、尿素氮、肌酐、胆红素均超出正常值上限的3倍,排除严重心肺 This article admitted to our hospital for cancer chemotherapy using thrombopoietin (rhTPO) for prevention and achieved good clinical results, are as follows. 1 Materials and Methods 1.1 Clinical data Retrospective analysis of the clinical data of 52 cases of malignant tumors admitted to our hospital from February 2007 to February 2012, all patients with malignant neoplasms after chemotherapy by pathology or cytology confirmed cytopenias , Platelet count were less than 75 × 109 / L, the expected survival of more than 3 months, serum aminotransferase, urea nitrogen, creatinine, bilirubin exceeded three times the upper limit of normal, excluding severe cardiopulmonary